503 Pneumonitis with anti-PD-1/PD-L1 therapy

Naidoo, Jarushka; Cunningham, Jane; Kyoung-Nam, Woo; Hellmann, M.; Postow, Michael A.; Drilon, Alexander; Chaft, Jamie E.; Lesokhin, Alexander M.; Segal, Neil H.; Callahan, Margaret K.; Rudin, C.; Iyriboz, Tunc; Wolchok, Jedd D.

doi:10.1016/s0959-8049(16)30305-7

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They show that there may be a relation between the CT scan patterns and the pneumonitis severity. This relation is in line with the results presented by Naidoo and colleagues at the 2015 European Cancer Congress (10). Although further research should be done, CT scan images may help us not only to diagnose but also to classify pneumonitis cases and to guide our therapeutic approach.…”

supporting

confidence: 88%

Anti-PD1–Induced Pneumonitis: Capturing the Hidden Enemy

Castañón

2016

Clinical Cancer Research

View full text Add to dashboard Cite

Anti-PD1 antibodies have led to a therapeutic shift in cancer treatment. Although classically described as "well tolerated," these drugs can lead to severe immune-related adverse events. Using CT scan imaging, Nishino and colleagues describe different radiologic patterns and their possible relation to severity of several cases of anti-PD1-induced pneumonitis. Clin Cancer Res; 22(24); 5956-8. ©2016 AACRSee related article by Nishino et al., p. 6051.

show abstract

supporting

confidence: 88%

Anti-PD1–Induced Pneumonitis: Capturing the Hidden Enemy

Castañón

2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Radiological abnormalities can be variable but are often focal and very different from the diffuse pneumonitis associated with targeted agents such as tyrosine kinase inhibitors (Figure ). A review of 653 patients with various cancers who received an anti‐PD‐1/PD‐L1 monoclonal antibody, either alone or in combination, found 36 cases (6%) of pneumonitis . Five distinct radiologic subtypes were identified: cryptogenic obstructive pneumonia (COP)‐like, ground‐glass opacities, hypersensitivity type, interstitial type, and pneumonitis not otherwise specified.…”

Section: Specific Iraesmentioning

confidence: 99%

“…Immune‐related pneumonitis, which is defined as a focal or diffuse inflammation of the lung parenchyma, is one of the few potentially life‐threatening irAEs. It occurs more commonly in patients with lung cancer than with other malignancies . Prior thoracic radiotherapy and preexisting chronic lung disease—especially interstitial lung disease, asthma, and chronic obstructive pulmonary disease—may increase the risk .…”

Section: Specific Iraesmentioning

confidence: 99%

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

et al. 2017

View full text Add to dashboard Cite

Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy.Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents. The Oncologist 2017;22:70-80Implications for Practice: The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multidisciplinary approach. Continued education is important for all physicians to ensure optimal care for patients.

show abstract

“…Of note, in one of the original studies of nivolumab in multiple tumor types, pneumonitis led to three treatment‐related deaths . Patients may present with symptoms of shortness of breath and cough most commonly, and several radiologic subtypes of anti‐PD‐1/PD‐L1‐associated pneumonitis have been described …”

Section: Immune‐related Adverse Events: Anti‐pd‐1/anti‐pd‐l1 Monotherapymentioning

confidence: 99%

Immune‐Related Adverse Events From Immune Checkpoint Inhibitors

Marrone

Ying

Naidoo

2016

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Immunotherapy for cancer treatment has come of age, specifically with the use of immune checkpoint antibodies directed against molecules such as CTLA-4, PD-1, and PD-L1. Single-agent and combinatorial approaches utilizing these agents and other immunotherapies that may enhance antitumor effects are under investigation. With increasing clinical use of these agents, an appreciation for their toxicities comes to the fore. Adverse events that occur as a result of the immunologic effects of these therapies are termed "immune-related adverse events" (irAEs), and range in both frequency and severity in reported single-agent and combination studies. Improvements in our understanding of how and why irAEs develop and how to effectively manage them are needed. Herein we provide a state-of-the-art synopsis of the incidence, clinical features, mechanisms, and management of selected irAEs with immune checkpoint inhibitors currently in use.

show abstract

503 Pneumonitis with anti-PD-1/PD-L1 therapy

Cited by 8 publications

References 0 publications

Anti-PD1–Induced Pneumonitis: Capturing the Hidden Enemy

Anti-PD1–Induced Pneumonitis: Capturing the Hidden Enemy

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

Immune‐Related Adverse Events From Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About